Once again, it looks like Wall Street’s biggest banks just missed out on one of the biggest deals of 2015.
On one side of the deal, projected to be worth about $US40 billion, is Teva Pharmaceuticals, which is aiming to buy its peer Mylan N.V. for $US82 per share in a cash-and-stock deal. Teva, according to a statement, is being advised by Greenhill & Co., a boutique bank that went public in 2004.
If that’s the case, it’s yet another big win for an advisor that has been taking a growing portion of big banks’ advisory fees, especially in 2015. And it’s part of a pattern of smaller banks displacing boutiques, especially on some big deals.
Representatives for Teva Pharmaceuticals did not immediately comment when contacted by Business Insider; Centerview did not immediately comment.